---
title: Medical Student Quick Topics
author: J. Austin Straley, DO
date: 2022-11-13
layout: post
category: msqt
published: true
permalink: /msqt
lesson: 6
importance: 1
---

<link rel="stylesheet" href="{{site.baseurl}}/assets/project-style.css">
<style>
html {
  scroll-behavior: smooth;
}
</style>

## <a name="Student/Intern Readings">Student/Intern Readings</a>
- M3/M4 Suggested Articles
    - [SIU Reading List](https://www.med.unc.edu/medclerk/wp-content/uploads/sites/877/2018/10/SIUreadinglist.pdf){:target="_blank"}
    - [UNC Suggested Reading](https://www.med.unc.edu/medclerk/resources/suggested-reading-topics/){:target="_blank"}
- [M4 ED Curriculum](https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m4-curriculum){:target="_blank"}
    - [Incomplete ER Journal Club Articles](https://wikem.org/wiki/Category:Incomplete_Journal_Club_Articles){:target="_blank"}
- Trial Pages
    - [Wiki Journal Club](https://www.wikijournalclub.org/wiki/Main_Page){:target="_blank"}
    - [2 Minute Medicine - The Classics - Summaries](https://www.2minutemedicine.com/the-classics-in-medicine-summaries-of-the-landmark-trials/){:target="_blank"}
    - [2 Minute Medicine - The Classics - Directory](https://www.2minutemedicine.com/the-classics-directory/){:target="_blank"} 
- ICU Guides
    [UOC](http://chicago.medicine.uic.edu/wp-content/uploads/sites/6/2017/09/icuguidebook.pdf){:target="_blank"} 
- [Bugs & Drugs](https://www.bugsanddrugs.org/){:target="_blank"} 
- [Tulane Pharmacy School Website](https://tmedweb.tulane.edu/pharmwiki/doku.php/start){:target="_blank"} 
- Drug Interaction Books
    - [Louisville Interactions - Adults](https://kdpnet.kdp.louisville.edu/drugbook/adult/?node=4547){:target="_blank"} 
    - [Louisville Interactions](https://kdpnet.kdp.louisville.edu/){:target="_blank"} 
- [EKG Practice](https://ecg.bidmc.harvard.edu/maven/mavenmain.asp){:target="_blank"} 
- Arrythmia Databases
    - [Physionet](https://physionet.org/content/mitdb/1.0.0/){:target="_blank"} 
    - [Physionet Database](https://archive.physionet.org/physiobank/database/html/mitdbdir/mitdbdir.htm){:target="_blank"} 
<br>

## <a href="#cardiology" class="anchor-section" aria-label="Anchor link to header">Cardiology</a>
- Atrial Fibrillation
    - [General](https://www.ncbi.nlm.nih.gov/books/NBK526072/){:target="_blank"}
    - Management
        - [General](https://pubmed.ncbi.nlm.nih.gov/30144419/){:target="_blank"}
        - [AFFIRM: Rate-control = Rhythm-control; Rate preferred due to Adverse events](https://pubmed.ncbi.nlm.nih.gov/12466506/){:target="_blank"}
        - [RACE-II: Lenient non-inferior to strict rate-control in afib](https://pubmed.ncbi.nlm.nih.gov/20231232/){:target="_blank"}
        - [RAAFT-2: RFA if AAD failed as 1st line for symptomatic PAF](https://pubmed.ncbi.nlm.nih.gov/24549549/){:target="_blank"}
        - [AVERROES: Eliquis > Aspirin for Stroke/VTE](https://pubmed.ncbi.nlm.nih.gov/21309657/){:target="_blank"}
        - [ARISTOTLE: Eliquis > Warfarin for stroke, less brain bleeding](https://pubmed.ncbi.nlm.nih.gov/21870978/){:target="_blank"}
        - [ROCKET-AF: Xarelto is non-inferior to Warfarin](https://pubmed.ncbi.nlm.nih.gov/21830957/){:target="_blank"}
        - [BRIDGE: Periprocedural bridging did not reduce ATE, increased bleeding](https://pubmed.ncbi.nlm.nih.gov/26095867/){:target="_blank"}
- Coronary Artery Disease (CAD)
    - Management
        - [4S: Statins reduce Death, MI, Revasc in Angina/MI patients](https://pubmed.ncbi.nlm.nih.gov/7968073/){:target="_blank"}
        - [SATURN: Crestor better LDL reduction, no better mortality than Lipitor](https://pubmed.ncbi.nlm.nih.gov/22085316/){:target="_blank"}
            - Atorvastatin (Lipitor)
                - [Muscle toxicity w/concurrent Amiodarone use (0.7%)](https://pubmed.ncbi.nlm.nih.gov/15860984/){:target="_blank"}
            - Rosuvastatin (Crestor)
                - [Crestor FDA (Renal Dosing)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021366s040s041lbl.pdf){:target="_blank"}
                - [Crestor to prevent vascular events in patients with elevated CRP](https://pubmed.ncbi.nlm.nih.gov/18997196/){:target="_blank"}
            - Side Effects
                - [Statin induced diabetes and its clinical implications](https://pubmed.ncbi.nlm.nih.gov/25210397/){:target="_blank"}
                - [Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis](https://pubmed.ncbi.nlm.nih.gov/21693744/){:target="_blank"}
                - [Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials](https://pubmed.ncbi.nlm.nih.gov/20167359/){:target="_blank"}
                - [Statin-Associated Myopathy](https://pubmed.ncbi.nlm.nih.gov/12672737/){:target="_blank"}
                    - [Adverse events with concomitant amiodarone and statin therapy](https://pubmed.ncbi.nlm.nih.gov/15860984/){:target="_blank"}
                - [Asymptomatic hypothyroidism and statin-induced myopathy](https://pubmed.ncbi.nlm.nih.gov/17872677/){:target="_blank"}
        - [COURAGE: PCI w/BMS in Stable CAD non-superior to medical therapy](https://pubmed.ncbi.nlm.nih.gov/17387127/){:target="_blank"}
        - [In life expectancy <1, discontinuation of statin did not increase 60-day mortality](https://pubmed.ncbi.nlm.nih.gov/20818875/){:target="_blank"}
- Chest Pain/Angina Pectoris
    - [Chest Pain in the ED (M4s)](https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m4-curriculum/group-m4-approach-to/chest-pain){:target="_blank"}
    - [HEART vs. TIMI vs. GRACE](https://www.internationaljournalofcardiology.com/article/S0167-5273(16)33282-X/fulltext){:target="_blank"}
    - [Diagnosis](https://pubmed.ncbi.nlm.nih.gov/34756653/){:target="_blank"}
        - [Update on Stress Testing](https://pubmed.ncbi.nlm.nih.gov/22469057/){:target="_blank"}
            - Not interpretable for ischemia if:
                - Old LBBB, unable to reach target HR, or baseline ST elevation or on Digoxin
                - Get Stress Testing with Imaging (MPI, CMR, or Echo) if unable to do Exercise Stress Test
                    - Indications
                        - Unable to exercise
                        - Baseline EKG abnormalities limiting interpretation
                        - Indeterminate findings on Exercise Stress Test 
                    - No adenosine in asthmatics, hypotension (stimulate A2A receptors on vascular smooth muscles, magnified from rest)
            - Positive Findings (Findings associated with poor outcomes)
                - Poor exercise capacity (<5 METs)
                - Exercise-induced angina during minimal expenditure
                - Inability to achieve 85% age-predicted maximum HR with exercise
                - Fall in SBP below baseline during exercise
                - ST elevation
                - ≥ 2mm ST-depression during minimal expenditure
                - Early onset or prolonged duration of ST depression during testing
                - ST depression in multiple leads
                - Ventricular couplets or tachycardia during minimal expenditure or recovery
            - Balanced Ischemia
                - High risk features on Exercise testing
                - Coronary blood low is equally or nearly equally impaired
                - ST depression in multiple leads during peak stress but no evidence of ischemia on radionuclide MPI
- Heart Failure 
    - [Physiology](https://derangedphysiology.com/main/cicm-primary-exam/required-reading/cardiovascular-system){:target="_blank"}
        - [Physiology of Diuretics in Acute Heart Failure](https://pubmed.ncbi.nlm.nih.gov/32164892/){:target="_blank"}
    - [Updating the role of natriuretic peptide levels in cardiovascular disease](https://pubmed.ncbi.nlm.nih.gov/22104459/){:target="_blank"}
        - [Impact of body mass and body composition on circulating levels of natriuretic peptides](https://pubmed.ncbi.nlm.nih.gov/16203929/){:target="_blank"}
        - [The paradox of low BNP levels in obesity](https://pubmed.ncbi.nlm.nih.gov/21523383/){:target="_blank"}
    - [Risk Assessment](https://pubmed.ncbi.nlm.nih.gov/31526538/){:target="_blank"}
    - Management 
        - [Correction to: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association](https://doi.org/10.1161/CIR.0000000000000449){:target="_blank"}
        - Acute
            - [ED Management of Acute Heart Failure](https://emergencymedicinecases.com/acute-heart-failure-management-pocus-oxygenation-ppv-havoc-scape/){:target="_blank"}
            - [Prognostic Biomarkers in the ED in HF](https://thoracickey.com/diagnostic-and-prognostic-biomarkers-in-emergency-department-heart-failure/){:target="_blank"}
            - [University of Michigan Guide](https://www.ncbi.nlm.nih.gov/books/NBK589894/){:target="_blank"}
            - [DOSE-AHF: High-dose loops > symptom improvement; intermittent = continuous](https://pubmed.ncbi.nlm.nih.gov/21366472/){:target="_blank"}
            - [STRONG-HF: Rapid up-titration of GDMT and close f/u reduced risk of 180-day all-cause death or HF readmission in AECHF admits](https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/12/05/14/33/strong-hf){:target="_blank"}  
                - [European Heart Journal](https://academic.oup.com/eurheartj/article/44/31/2947/7175273){:target="_blank"}
        - Chronic
            - [2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure](https://pubmed.ncbi.nlm.nih.gov/35379504/){:target="_blank"}
            - [Diuretic Therapy for HF (JACC State-of-the-Art Review)](https://pubmed.ncbi.nlm.nih.gov/32164892/){:target="_blank"}
                - [JACC Diuretic Therapy](https://www.jacc.org/doi/10.1016/j.jacc.2019.12.059){:target="_blank"}
            - [Optimal Diuretic Strategies in HF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039650/){:target="_blank"}
            - [Chronic Stable HF Optimization](https://pubmed.ncbi.nlm.nih.gov/29277252/){:target="_blank"}
        - GDMT
            - [ACEI in Asymptomatic LV dysfunction](https://pubmed.ncbi.nlm.nih.gov/1463530/){:target="_blank"}
            - [REVERT: BBs Reverse LV remodeling in asymptomatic LV systolic dysfunction](https://pubmed.ncbi.nlm.nih.gov/17576868/){:target="_blank"}
            - [PARADIGM-HF: Entresto reduced CV risk and Hospitalizations vs. ACEI](https://pubmed.ncbi.nlm.nih.gov/25176015/){:target="_blank"}
            - MRAs
                - [Eplerenone in patients with HF and mild symptoms](https://pubmed.ncbi.nlm.nih.gov/21073363/){:target="_blank"}
                - [RALES: Spironolactone reduces morbidity/mortality in severe HFrEF](https://pubmed.ncbi.nlm.nih.gov/10471456/){:target="_blank"}
            - [SGLT2 better than Sitagliptin (Primary outcome: 13.1% vs. 17.4%)](https://academic.oup.com/eurheartj/article/44/24/2216/7187574){:target="_blank"}
            - [Persistent Severe HF symptoms on maximal GDMT](https://pubmed.ncbi.nlm.nih.gov/32216916/){:target="_blank"}
        - Inotropes
            - [Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controlled study](https://pubmed.ncbi.nlm.nih.gov/12939113/){:target="_blank"}
            - [Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial](https://pubmed.ncbi.nlm.nih.gov/11911756/){:target="_blank"}
        - [FAIR-HF: Anemia (ferritin <100, or 100-300 w/Tsat <20%) + HFrEF (EF ≤45%) improved 6m walk, QOL and NYHA functional Class](https://pubmed.ncbi.nlm.nih.gov/19920054/){:target="_blank"}
        - Exercise training/cardiac rehabilitation 
            - [Improves functional capacity and overall quality of life](https://pubmed.ncbi.nlm.nih.gov/25605639/){:target="_blank"}
            - [QOL](https://pubmed.ncbi.nlm.nih.gov/25399909/){:target="_blank"}
- Hyperlipidemia
    - [2018 Guideline on the Managment of Blood Cholesterol](https://pubmed.ncbi.nlm.nih.gov/30586774/){:target="_blank"}
    - Hypertriglyceridemia
        - [2021 ACC Guideline for the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia](https://pubmed.ncbi.nlm.nih.gov/34332805/){:target="_blank"}
- Hypertension
    - [Management](https://pubmed.ncbi.nlm.nih.gov/29146535/){:target="_blank"}
        - [DASH: Small but significant BP reductions from diet control](http://www.ncbi.nlm.nih.gov/pubmed/9099655){:target="_blank"}
        - [LIFE: Losartan > Atenolol for same BP Reduction](https://pubmed.ncbi.nlm.nih.gov/11937179/){:target="_blank"}
        - [ALLHAT: Thiazide = CCB = ACEI in High-risk HTN, Thiazides may be better](https://pubmed.ncbi.nlm.nih.gov/12479763/){:target="_blank"}
        - [ACCOMPLISH: CCBs > Diuretics when added to ACEI in High-risk HTN](https://pubmed.ncbi.nlm.nih.gov/19052124/){:target="_blank"}
        - [Thiazides less effective in obese, CCBs equal across weight](https://pubmed.ncbi.nlm.nih.gov/23219284/){:target="_blank"}
        - [HOPE: ACEI significantly reduces rate of HF in High-risk patients](https://pubmed.ncbi.nlm.nih.gov/12628949/){:target="_blank"}
        - Inpatient
            - [Asymptomatic Inpatient Hypertension](https://pubmed.ncbi.nlm.nih.gov/30811320/){:target="_blank"}
            - [Things We Do For No Reason: Antihypertensives Inpatient](https://shmpublications.onlinelibrary.wiley.com/doi/10.1002/jhm.13185){:target="_blank"}
            - [Hydralazine vs. Labetalol Inpatient](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673377/){:target="_blank"}
        - [Resistant Hypertension](https://pubmed.ncbi.nlm.nih.gov/27895136/){:target="_blank"}
- Myocardial Infarction
    - [Definition](https://pubmed.ncbi.nlm.nih.gov/30153967/){:target="_blank"}
    - Management
        - P2Y12
            - [PLATO: Ticagrelor > Clopidogrel in ACS including mortality](http://www.ncbi.nlm.nih.gov/pubmed/19717846){:target="_blank"}
            - [DAPT: Continuing Thienopyridine after 12 months decreased risk of In-stent thrombosis and MI at 18 months, increased risk of bleeding](https://pubmed.ncbi.nlm.nih.gov/25399658/){:target="_blank"}
            - [WOEST: Bleeding w/AC + Plavix < Triple Therapy w/o change in MI/Stroke/MACE](https://pubmed.ncbi.nlm.nih.gov/23415013/){:target="_blank"}
            - [COGENT: PPI with DAPT reduces GIB 87%, no CV event change](https://pubmed.ncbi.nlm.nih.gov/20925534/){:target="_blank"}
        - Statin
            - [PROVE-IT: Significantly reduced CVD events following MI with High-dose Lipitor vs. Pravastatin](http://www.ncbi.nlm.nih.gov/pubmed/15007110){:target="_blank"}
        - ACEI
            - [SAVE: ACEI improve survival/morbidity/mortality in LV dysfunction after MI](https://pubmed.ncbi.nlm.nih.gov/1386652/){:target="_blank"}
        - [MADIT-II: ICD improves survival in pts with prior MI and severe LV dysfunction](https://pubmed.ncbi.nlm.nih.gov/11907286/){:target="_blank"}
- Syncope
    - [Incidence and Prognosis](https://pubmed.ncbi.nlm.nih.gov/12239256/){:target="_blank"}
    - [Etiology and Diagnostic Approach](https://pubmed.ncbi.nlm.nih.gov/16418451/){:target="_blank"}
        - [Syncope: etiology and diagnostic approach](https://pubmed.ncbi.nlm.nih.gov/25452354/){:target="_blank"}
        - [Unexplained syncope--is screening for carotid sinus hypersensitivity indicated in all patients aged >40 years?](https://pubmed.ncbi.nlm.nih.gov/16735395/){:target="_blank"}
    - Sudden transient loss of consciousness with associated loss of postural tone and spontaneous recovery 
        - Results from transient cerebral hypoperfusion
    - W/U: H+P, EKG, Labs (CBC, CMP, SaO2, Cardiac Enzymes)  
        - Recurrent syncope, cardiac cause ruled out, atypical presentation, high risk occupation with single episode: Tilt-table tasting
            - 26-80% sensitive, 90% specific
        - Admit if any High risk (ROSE rule, BRACES):
            - High-Risk Features(≥1 feature increases the short-term risk of significant death or arrythmia)
                - Abnormal EKG (new change)
                    - Diagnosis in 60%
                - History of structural heart disease or heart failure
                    - Aortic Stenosis
                - Systolic BP <90mmHg at triage
                - Associated shortness of breath during syncope
                - Hematocrit <30%
                - Advanced age with CV comorbidities
                - Family history of sudden cardiac death
            - BNP ≥300
            - Bradycardia ≤50
            - Rectal exam with FOB
            - Anemia (≤90)
            - Chest pain with syncope
            - EKG with Q wave (not in lead III)
            - Saturation ≤94% on RA
    - Diagnosis and Management
        - [No cause found: San Francisco Syncope Rules](https://pubmed.ncbi.nlm.nih.gov/21948723/){:target="_blank"}
        - [Transient loss of consciousness synopsis of NIH guidelines](https://pubmed.ncbi.nlm.nih.gov/21930835/){:target="_blank"}
        - [Association between symptoms and frequency of arrhythmias on 24-hour Holter monitoring](https://pubmed.ncbi.nlm.nih.gov/19889262/){:target="_blank"}
        - [Usefulness of 24hr Holter monitoring in unexplained syncope and high likelihood of arrythmias](https://pubmed.ncbi.nlm.nih.gov/15882664/){:target="_blank"}
    - Management
        - [AAFP](https://www.aafp.org/pubs/afp/issues/2011/0915/p640.html){:target="_blank"}
        - [European Guidelines 2009](https://pubmed.ncbi.nlm.nih.gov/19713422/){:target="_blank"}
        - [Guideline for the Evaluation and Management of Patients With Syncope](https://pubmed.ncbi.nlm.nih.gov/28280232/){:target="_blank"}
        - All Patient: Orthostatic Vitals and EKG
            - Low-Risk: Ambulatory ECG monitor
            - Intermediate-Risk: Observation inpatient
            - High-Risk: Admission
<br>

## Dermatology
- Actinic Keratosis
    - Mc benign lesion with malignant potential
        - Caused by chronic sun exposure
            - [Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation](https://pubmed.ncbi.nlm.nih.gov/20865846/){:target="_blank"}
            - [Epidemiology of actinic keratoses and squamous cell carcinoma](https://pubmed.ncbi.nlm.nih.gov/10607349/){:target="_blank"}
    - Precursor lesion to SCC
        - [Up to 60% of cutaneous SCCs arise from preexisting AKs](https://pubmed.ncbi.nlm.nih.gov/19382202/){:target="_blank"}
- Cutaneous Tumors
    - [Systematic skin cancer screening in Northern Germany](https://pubmed.ncbi.nlm.nih.gov/22074699/){:target="_blank"}
    - [Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria](https://pubmed.ncbi.nlm.nih.gov/15585738/){:target="_blank"}
    - [Biopsy for malignant melanoma--are we following the guidelines?](https://pubmed.ncbi.nlm.nih.gov/18492398/){:target="_blank"}
<br>

## <a href="Endocrinology">Endocrinology</a>
- Diabetes Mellitus
    - [Inpatient Management](https://www.ccjm.org/content/83/5_suppl_1/S34){:target="_blank"}
    - [ACCORD: A1c target <6.0% increased CV and all-cause mortality vs standard (7.0-7.9%)](https://www.nejm.org/doi/full/10.1056/nejmoa0802743){:target="_blank"}
    - [RABBIT-2: Basal-Bolus > SSI](https://pubmed.ncbi.nlm.nih.gov/17513708/){:target="_blank"}
    - [FREEDOM: All-cause mortality is improved with CABG > PCI w/DES in T2DM](https://pubmed.ncbi.nlm.nih.gov/18215589/){:target="_blank"}
    - [NICE-SUGAR: Intensive glucose control increased mortality in ICU patients](https://pubmed.ncbi.nlm.nih.gov/19318384/){:target="_blank"}
    - [CREDENCE: Canagliflozin 100mg/d reduces risk of ESRD and death](https://pubmed.ncbi.nlm.nih.gov/30990260/){:target="_blank"}
- DKA
    - [Management](https://pubmed.ncbi.nlm.nih.gov/25061324/){:target="_blank"}
- Hypothyroidism
    - [Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association](https://pubmed.ncbi.nlm.nih.gov/23246686/){:target="_blank"}
    - Labs
        - TSH then Free Thyroxine (FT4)
            - TSH elevated: overt/subclinical
            - FT4 low: overt only
        - T3 recommended if any:
            - Evaluation of thyrotoxicosis
            - T3 Toxicosis: T3:T4 > 20
        - Assess severity of hyperthyroidism and response to therapy
        - Differentiate hyperthyroidism from destructive thyroidism
            - T3 if low
            - https://pubmed.ncbi.nlm.nih.gov/21510801/
            - https://pubmed.ncbi.nlm.nih.gov/1569166/
- Hyperthyroidism
    - [General](https://pubmed.ncbi.nlm.nih.gov/21510801/){:target="_blank"}
<br>

## Gastroenterology (GI)
- Cirrhosis
    - [Ceftriaxone reduces bacterial infection 67% in GIB, no survival benefit vs. norfloxacin](https://pubmed.ncbi.nlm.nih.gov/17030175/){:target="_blank"}
    - [SBP on IV ABX, IV Albumin reduces renal impairment and mortality (1.5g/kg at diagnosis and 1 g/kg on day 3)](https://pubmed.ncbi.nlm.nih.gov/10432325/){:target="_blank"}
- GERD
- PUD
    - [PPI Potency](https://www.cghjournal.org/article/S1542-3565(17)31168-0/pdf){:target="_blank"}
- Cholelithiasis
- Jaundice
- GI Bleeding
    - [Endoscopy timing for UGIB](https://www.nejm.org/doi/full/10.1056/NEJMoa1912484){:target="_blank"}
    - [Transfusion strategies for acute UGIB (≥7 better mortality benefits than ≥10)](https://www.nejm.org/doi/full/10.1056/nejmoa1211801){:target="_blank"}
    - [Transfusion strategies](https://pubmed.ncbi.nlm.nih.gov/23281973/){:target="_blank"}
- Transaminitis
    - [Mildly Elevated Liver Transaminase Levels: Causes and Evaluation](https://pubmed.ncbi.nlm.nih.gov/29431403/){:target="_blank"}
- Viral Hepatitis
    - [VALENCE: Sofosbuvir-ribavirin for HCV genotypes 2 or 3](https://pubmed.ncbi.nlm.nih.gov/24795201/){:target="_blank"}
<br>

## General
- Alcohol Use/Drug Use
    - [Symptom-triggered > Fixed Benzodiazepine treatment for alcohol withdrawal](https://pubmed.ncbi.nlm.nih.gov/12020181/){:target="_blank"}
- Depression
    - [STAR*D I: Adding bupropion or buspirone achieves remission in 30%](https://pubmed.ncbi.nlm.nih.gov/17074942/){:target="_blank"}
    - STAR*D II: When citalopram fails, remission induced in 25% when switched to ER bupropion, sertraline, or ER venlafaxine
- Lab Errors
    - A1c
        - [Pitfalls in hemoglobin A1c measurement: when results may be misleading](https://pubmed.ncbi.nlm.nih.gov/24002631/){:target="_blank"}
- Obesity
    - Lifestyle Modifications
        - Relative Merits of Low-Carbohydrate Versus Low-Fat Diet in Managing Obesity
            - [Both Equivalent for Weight loss at 1 year](https://pubmed.ncbi.nlm.nih.gov/26192936/){:target="_blank"}
            - [Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of RCTs](https://pubmed.ncbi.nlm.nih.gov/23035144/){:target="_blank"}
        - Low-Fat Diet
        - Low-Carbohydrate Diet
            - Rapid initial weight loss
            - Associated with reduced CV risk and All-cause mortality in observational studies
            - Associated with increased incidence of unpleasant GI side effects
            - [A critical review of low-carbohydrate diets in people with Type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/26413954/){:target="_blank"}
    
- PADUA
    - [DVT PPX](https://pubmed.ncbi.nlm.nih.gov/20738765/){:target="_blank"}
- QTc Prolongation
    - [The Risk of QTc interval Prolongation with Psychotropics](https://mghcme.org/app/uploads/2020/10/Celano-Academy-Course-QTc-2020.pdf){:target="_blank"}
    - [Which psychotropics carry the greatest risk of QTc prolongation?](https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/1110CP_SavvyPsych.pdf){:target="_blank"}
    - [Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients](https://pubmed.ncbi.nlm.nih.gov/29317399/){:target="_blank"}
- Urinary Incontinence
    - [Overview](https://pubmed.ncbi.nlm.nih.gov/27734727/){:target="_blank"}
    - [Treatment](https://pubmed.ncbi.nlm.nih.gov/26088072/){:target="_blank"}
<br>

## Geriatrics
- Normal Aging
- Delirium/Dementia
    - [MIND-USA: Haldol/Ziprasidone no improvement in days alive without delirium/coma](https://pubmed.ncbi.nlm.nih.gov/30346242/){:target="_blank"}
    - [DELIRIA-J: Ramelteon reduced delirium](https://pubmed.ncbi.nlm.nih.gov/24554232/){:target="_blank"}
    - [Dementia](https://www.vim-book.org/geriatrics/geriatrics-dementia/){:target="_blank"}
- Depression
    - [Depression and cognition in the elderly](https://pubmed.ncbi.nlm.nih.gov/25581234/){:target="_blank"}
    - [Diagnosis and treatment of depression and cognitive impairment in late life](https://pubmed.ncbi.nlm.nih.gov/25655026/){:target="_blank"}
    - [Mirtazapine: May be better than Sertraline in Geriatric Depression](https://pubmed.ncbi.nlm.nih.gov/23995195/){:target="_blank"}
    - [Review of the use of mirtazapine in the treatment of depression](https://pubmed.ncbi.nlm.nih.gov/21644844/){:target="_blank"}
- [HYVET: ≥80, treatment w/diuretic w/ or w/o ACEI trends toward reduced death/stroke](https://pubmed.ncbi.nlm.nih.gov/18378519/){:target="_blank"}
<br>

## Hematology
- Anemia
    - Anemia of Chronic Disease
        - [Advancements in anemias related to chronic conditions](https://pubmed.ncbi.nlm.nih.gov/20618092/){:target="_blank"}
    - Transfusion thresholds
        - [TRICC: Better survival in critically ill with Hgb target of >7 than >10](https://pubmed.ncbi.nlm.nih.gov/9971864/){:target="_blank"}
        - [TRISS: Similar mortality with Hgb target of >7 than >9 in septic shock](https://pubmed.ncbi.nlm.nih.gov/25270275/){:target="_blank"}
- Breast Cancer
    - [ATLAS: In ER+ BC, tamoxifen for 10 years reduced recurrence/mortality, increased endometrial cancer and PE risk](https://pubmed.ncbi.nlm.nih.gov/23219286/){:target="_blank"}
- Chronic Leukemia
    - CLL
        - [Ibrutinib-Rituximab > FCR if <70 y/o and untreated](https://pubmed.ncbi.nlm.nih.gov/31365801/){:target="_blank"}
    - CML
        - [IRIS: Imantinib > IFNa/cytarabine in delaying disease progression](https://pubmed.ncbi.nlm.nih.gov/12637609/){:target="_blank"}
- DIC
- General
    - [Multiple CTs increase risk of leukemia and brain tumors](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60815-0/fulltext/){:target="_blank"}
- Iron Deficiency Anemia
    - [Consensus Statement on Peri-operative management of Anemia and IDA](https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.13773/){:target="_blank"}
    - [IRONMAN: IV Iron not better than placebo, did not change # of pRBC transfusion during stay](https://pubmed.ncbi.nlm.nih.gov/27686346/){:target="_blank"}
- Lymphomas
- Thrombocytopenia
    - [EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact](https://pubmed.ncbi.nlm.nih.gov/22868791/){:target="_blank"}
    - [Drug-induced thrombocytopenia](https://pubmed.ncbi.nlm.nih.gov/20008194/){:target="_blank"}
        - [PubMed](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413903/){:target="_blank"}
- VTE
    - [SOME: Not better to screen for occult malignancy in first unprovoked VTE](https://www.nejm.org/doi/full/10.1056/NEJMoa1506623/){:target="_blank"}
    - [AMPLIFY: Oral Apixaban for the Treatment of Acute VTE](https://www.nejm.org/doi/full/10.1056/NEJMoa1302507/){:target="_blank"}
    - PE
        - [Causes of Elevated D-Dimer](https://www.njmonline.nl/article_ft.php?a=1790&d=1189&i=201){:target="_blank"}
        - [ADJUST-PE: Age-adjusted D-Dimer (Age x 10) in patients >50 r/o more pts](https://pubmed.ncbi.nlm.nih.gov/24643601/){:target="_blank"}
        - [ERC/PROPER: Low suspicion and PERC(-) reduces VTE probability to <2%](https://pubmed.ncbi.nlm.nih.gov/18318689/){:target="_blank"}
            - [Also](https://pubmed.ncbi.nlm.nih.gov/29450523/){:target="_blank"}
        - [PIOPED II: CTA is sensitive (90%) and specific (95%) for PE](https://pubmed.ncbi.nlm.nih.gov/16738268/){:target="_blank"}
    - DVT
        - Wells DVT Criteria
            - [Rule-Out with Negative D-Dimer](https://www.nejm.org/doi/full/10.1056/NEJMoa023153/){:target="_blank"}
            - [Diagnosis/Treatment](https://pubmed.ncbi.nlm.nih.gov/17060659/){:target="_blank"}
            - [Treatment](https://pubmed.ncbi.nlm.nih.gov/22315257/){:target="_blank"}
        - CLOT: Dalteparin > Warfarin in preventing recurrent VTE of malignancy
<br>

## Infectious Disease
- AIDS
    - [INSIGHT-START: Early initiation of anti-retroviral therapy for HIV](https://www.nejm.org/doi/full/10.1056/NEJMoa1506816/){:target="_blank"}
- Bronchitis
- Cellulitis
    -  [Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America](https://academic.oup.com/cid/article/59/2/147/442347?login=false){:target="_blank"}
- Necrotizing Soft Tissue Infections
    - [Review](https://pubmed.ncbi.nlm.nih.gov/17599015/){:target="_blank"}
- Pneumonia
    - CURB-65 Score
    - [CAP-START: B-Lactam was noninferior to quinolone or combo B-Lactam + Macrolide](https://pubmed.ncbi.nlm.nih.gov/25830421/){:target="_blank"}
    - [Diagnosis and Management](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812437/){:target="_blank"}
- Procalcitonin
    - [FDA approved for initiating or discontinuing ABX in LRTIs and for discontinuing antibiotics in patients with sepsis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885331/){:target="_blank"}
    - [Cost effectiveness ($2704 more per patient than those who didn’t, not good)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234639/){:target="_blank"}
    - [Cutoffs for specific diseases](https://www.ncbi.nlm.nih.gov/books/NBK539794/){:target="_blank"}
- UTI
    - [Uncomplicated Cystitis](https://uroweb.org/guidelines/urological-infections/related-content/){:target="_blank"}
    - [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMcp1104429/){:target="_blank"}
    - [Americal Urologic Society](https://www.auanet.org/guidelines-and-quality/guidelines/recurrent-uti/){:target="_blank"}
- Wound Care
    - [Common questions about wound care](https://pubmed.ncbi.nlm.nih.gov/25591209/){:target="_blank"}
    - [Management of Pressure Ulcers](https://pubmed.ncbi.nlm.nih.gov/15487879/){:target="_blank"}
    - [Evaluation and treatment](https://pubmed.ncbi.nlm.nih.gov/28027261/){:target="_blank"}
<br>

## Neurology
- [Canadian Head CT Ruie: 7 predictors for the need for minor head injuries](https://pubmed.ncbi.nlm.nih.gov/11356436/){:target="_blank"}
- Migraine
    - [Management](https://pubmed.ncbi.nlm.nih.gov/28384749/){:target="_blank"}
- Multiple Sclerosis
    - [TRANSFORMS: Fingolimod > INF Beta-1a in preventing relapse in MS](https://www.nejm.org/doi/full/10.1056/nejmoa0907839/){:target="_blank"}
    - [DEFINE: BG-12 reduces relapse rate in MS](https://pubmed.ncbi.nlm.nih.gov/22992073/){:target="_blank"}
- Stroke
    - TIA
    - [ABCD2 Score](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60150-0/fulltext/){:target="_blank"}
    - [SPARCL: High-dose atorvastatin reduces risk of fatal ischemic stroke in recent TIA/Stroke](https://pubmed.ncbi.nlm.nih.gov/16899775/){:target="_blank"}
<br>

## Nephrology
- Acute Renal Failure
    - [AKI](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf){:target="_blank"}
    - [Uric Acid as a Prognostic factor for in-hospital mortality in AKI](https://pubmed.ncbi.nlm.nih.gov/37073630/){:target="_blank"}
    - [AKIKI: Early vs. Late in Severe AKI in the ICU; No difference in mortality](https://pubmed.ncbi.nlm.nih.gov/27181456/){:target="_blank"}
    - [IDEAL-ICU: AKI w/Sepsis in the ICU; No difference in mortality](https://pubmed.ncbi.nlm.nih.gov/30304656/){:target="_blank"}
        - [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa1803213/){:target="_blank"}
- Chronic Kidney Disease
    - [ADVANCE: Intensive glycemic control (≤180) reduces risk of nephropathy](https://www.nejm.org/doi/full/10.1056/nejmoa0802987){:target="_blank"}
    - [CHOIR: Treating to a lower Hgb target with EPO reduced MI/Death/CHF/Stroke in Anemia with CKD; no conferred survival with target >13](https://pubmed.ncbi.nlm.nih.gov/17108343/){:target="_blank"}
    - [RENAAL: In T2DM and Nephropathy, Losartan 50-100 reduced ESRD risk](https://pubmed.ncbi.nlm.nih.gov/11565518/){:target="_blank"}
    - [IDEAL: Early vs. Late Dialysis in CKD; No survival difference](https://pubmed.ncbi.nlm.nih.gov/20581422/){:target="_blank"}
- Fluids/Electrolytes
    - [SALT-ED: No reduction in hospitalization duration; reduction in major kidney-events with balanced crystalloids (LR/Normosol)](https://pubmed.ncbi.nlm.nih.gov/29485926/){:target="_blank"}
    - Hypercalcemia
        - [Differential Diagnosis](https://pubmed.ncbi.nlm.nih.gov/1763670/){:target="_blank"}
<br>

## Oncology
- Breast Cancer
- Chemotherapy
    - General
        - Increased risk of MDS, Mixed MDS/MPN, and AML (10-20% of all cases of these cancers are chemotherapy related)
            - [Therapy-Related Myeloid Leukemia](https://pubmed.ncbi.nlm.nih.gov/18692692/){:target="_blank"}
            - [Etiology and management of therapy-related myeloid leukemia](https://pubmed.ncbi.nlm.nih.gov/18024664/){:target="_blank"}
    - Common Regimens
        - ABVD
            - Adriamycin, Bleomycin, Vinblastine, Dacarbazine
            - Hodgkin Lymphoma
        - BEACOPP
            - Bleomycin, Etoposide, Adriamycin/doxorubicin, Cyclophosphamide, Oncovorin/vincristine, Procarbazine, Prednisone
            - Hodgkin Lymphoma
        - FOLFIRI
            - Leucovorin, 5-Fluorouracil, Irinotecan
            - Advanced-stage and Metastatic Colorectal Cancer
        - FOLFOX
            - Leucovorin, 5-Fluorouracil, Oxaliplatin
        - R-CHOP
            - Rituximab, Cyclophosphamide, Hydroxy-doxorubicin, Oncovorin/Vincristine, Prednisone
<br>

## Pulmonology
- Acute Respiratory Failure
    - [Noninvasive Ventilation for ARF](https://www.thoracic.org/statements/resources/cc/niv-guidelines.pdf 
- ARDS
    - [Mechanical Ventilation in ARDS](https://pubmed.ncbi.nlm.nih.gov/28459336/){:target="_blank"}
    - [ACURASYS: Neuromuscular blockade in 1st 48hrs reduced 28- and 90-day mortality](https://pubmed.ncbi.nlm.nih.gov/20843245/){:target="_blank"}
    - [PROSEVA: Proning in severe ARDS reduced 28- and 90-day mortality](https://pubmed.ncbi.nlm.nih.gov/23688302/){:target="_blank"}
- Asthma
    - [Novel START: Prn Budesonide+formoterol reduced risk of exacerbations vs. Albuterol](https://pubmed.ncbi.nlm.nih.gov/31112386/){:target="_blank"}
    - [AMAZES: Azithromycin reduced rate of asthma exacerbations, improved QOL in severe](https://pubmed.ncbi.nlm.nih.gov/28687413/){:target="_blank"}
- COPD
    - Treatment
        - Antibiotics
        - [AECOPD](https://pubmed.ncbi.nlm.nih.gov/18321904/){:target="_blank"}
            - [REDUCE: 5d is non-inferior to 14d for prevention of re-AECOPD](http://www.ncbi.nlm.nih.gov/pubmed/23695200/){:target="_blank"}
        - [Pharmacotherapy](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193862/){:target="_blank"}
            - [FLAME: LABA + LAMA > LABA + ICS if mMRC ≥2 for exacerbations](http://www.ncbi.nlm.nih.gov/pubmed/27181606/){:target="_blank"}
            - [UPLIFT: Tiotropium associated with improvements in lung function, QOL, and exacerbations during 4-year period; did not reduce rate of FEV1 decline](https://www.nejm.org/doi/full/10.1056/nejmoa0805800){:target="_blank"}
- ICU
    - [EMCRIT: Fluids/Electrolytes](https://emcrit.org/ibcc/toc/#nephrology/){:target="_blank"}
    - [3SITES: Subclavian less CLABSIs and DVTs than jugular/femoral, more PTX](https://pubmed.ncbi.nlm.nih.gov/26398070/){:target="_blank"}
    - [65: MAP target 60-65 in pts ≥65 did not have mortality difference in vasodilatory shock](https://pubmed.ncbi.nlm.nih.gov/32049269/){:target="_blank"}
    - [Routine vs. On-Demand CXR in MV pts in the ICU increases use 34%, no benefit](https://pubmed.ncbi.nlm.nih.gov/19896184/){:target="_blank"}
    - [LACTATE: Decreased in-hospital mortality and shorter ICU stay with aim of 20% reduction q2hrs for the first 8 hours in ICU; guided group received more fluids and started vasopressors earlier but did not have faster rate of reduction in lactate](https://pubmed.ncbi.nlm.nih.gov/20463176/){:target="_blank"}
    - [PRORATA: <10% increase in mortality at 30-60 days with procalcitonin-guided ABX](https://pubmed.ncbi.nlm.nih.gov/20097417/){:target="_blank"}
    - [SPICE-III: Precedex had more ADE w/o improving mortality as primary sedative in MV](https://pubmed.ncbi.nlm.nih.gov/31112380/){:target="_blank"}
    - [SOAP-II: Dopamine = NE for 1st line; Dopamine has increased risk of arrhythmias](https://pubmed.ncbi.nlm.nih.gov/20200382/){:target="_blank"}
    - Septic Shock
        - [Surviving Sepsis Campaign](https://pubmed.ncbi.nlm.nih.gov/18158437/){:target="_blank"}
- Interstitial Lung Disease (ILD) 
    - [IPF](https://pubmed.ncbi.nlm.nih.gov/30168753/){:target="_blank"}
    - [Sarcoidosis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159433/){:target="_blank"}
- Lung Cancer
    - [National Lung Cancer Screening Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa1102873){:target="_blank"}
    - [Early Palliative care in metastatic NSCLC improves QOL and improved survival](https://pubmed.ncbi.nlm.nih.gov/20818875/){:target="_blank"}
- Pleural Effusion
    - [Lights Criteria for Pleural Effusions](https://www.acpjournals.org/doi/10.7326/0003-4819-77-4-507){:target="_blank"}
    - Management
        - [Management of infectious processes of the pleural space: a review](https://pubmed.ncbi.nlm.nih.gov/22536502/){:target="_blank"}
        - [Malignant Pleural Effusions](https://pubmed.ncbi.nlm.nih.gov/30272503/){:target="_blank"}
- Sleep Apnea
    - [Evaluation and Management of Obesity Hypoventilation Syndrome](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680300/){:target="_blank"}
<br>

## Rheumatology
- ANCA-Associated Vasculitis
    - [RAVE: Rituximab is non-inferior to Cyclophosphamide in inducing remission](https://pubmed.ncbi.nlm.nih.gov/20647199/){:target="_blank"}
- Ankylosing Spondylitis
- Gout
    - [Management](https://pubmed.ncbi.nlm.nih.gov/32391934/){:target="_blank"}
    - [Systemic corticosteroids for acute gout](https://pubmed.ncbi.nlm.nih.gov/18425920/){:target="_blank"}
    - [Managing gout: how is it different in patients with chronic kidney disease?](https://pubmed.ncbi.nlm.nih.gov/21147946/){:target="_blank"}
- OA
    - [Management](https://pubmed.ncbi.nlm.nih.gov/20809663/){:target="_blank"}
- Polymyalgia Rheumatica
    - [Overview](https://pubmed.ncbi.nlm.nih.gov/6982645/){:target="_blank"}
- *Pseudogout
    - [RF](https://pubmed.ncbi.nlm.nih.gov/22886340/){:target="_blank"}
- RA
    - [TICORA: Intensive > standard therapy in improving disease control at 18 months](http://www.ncbi.nlm.nih.gov/pubmed/15262104/){:target="_blank"}
- Septic Arthritis
    - [Sensitivity of ESR and CRP in ruling out Septic Arthritis](https://pubmed.ncbi.nlm.nih.gov/20655163/){:target="_blank"}
<br>

## Medications
- Antibiotics
    - 50S Inhibitors
        - Linezolid
            - No more than 28 days recommended, weekly CBC for possible bone marrow suppression
            - SE: Thrombocytopenia (30%), Pure Red Cell Aplasia, Neutropenia, Pancytopenia (>2 weeks), Peripheral neuropathy, Lactic Acidosis
                - Optic Neuropathy
                    - Optic disc edema, hyperemia, reduced color perception
                    - Typically after long-term use (>4 weeks)
                    - [May be irreversible, periodic eye and neurological exams for long courses](https://pubmed.ncbi.nlm.nih.gov/16505322/){:target="_blank"}
                - [Serotonin Syndrome, Lactic Acidosis](https://pubmed.ncbi.nlm.nih.gov/17655517/){:target="_blank"}
- Anti-Thrombotics
    - Antiplatelet Drugs
        - Clopidogrel (Plavix)
            - Efficacy decreased with omeprazole
                - Consider switching to different PPI (except esomeprazole) or H2RA (except cimetidine)
                    - [Clopidogrel with or without omeprazole in coronary artery disease](https://pubmed.ncbi.nlm.nih.gov/20925534/){:target="_blank"}
                    - [ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines](https://pubmed.ncbi.nlm.nih.gov/21060077/){:target="_blank"}
                    - [Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy](https://pubmed.ncbi.nlm.nih.gov/23425521/){:target="_blank"}
            - Pantoprazole (weak CYP2C19, favored)
                - Decrease GIB in DAPT in high risk patients
                    - Prior GIB, Age >65, PUD, H. Pylori
    - Anticoagulants
        - A. Vitamin K Antagonists
            - Warfarin (Coumadin)
                - MOA: Vitamin K epoxide reductase inhibitor
                    - Inhibits Prothrombin (II), VII, IX, X, C, S
                - CI: Pregnancy (crosses placenta)
                    - Vit k, nasal hypoplasia, stippled epiphyses in first trimester
                - Warfarin Metabolism
                    - CYP450 Inhibitors (Increased Warfarin effect)
                        - Risk of Hemorrhage
                        - Acetaminophen, NSAIDs, Metronidazole, Amiodarone, Cimetidine, Cranberry Juice, Ginkgo biloba, VitE, omeprazole, Thyroid hormone, SSRIs
                    - CYP450 Inducers (Decreased Warfarin effect)
                        - Risk of Thrombosis
                        - Carbamazepine, Phenytoin, Ginseng, St. John Wort, OCPs, Phenobarbital, Rifampin, Spinach/Sprouts (Vitamin K)
        - B. Factor Xa Inhibitors
            - I. Heparins/Glycosaminoglycans/Binds Antithrombin
                - A. Unfractionated Heparin (UFH) (Parenteral)
                    - Must monitor using aPTT
                    - Dose dependent, saturable, weaker binding to endothelial, macrophage, hbpps
                    - Activates Antithrombin (III) ≥ binds fibrin
                        - Accelerates Antithrombin clot inhibition
                        - Inhibiting Thrombin and Factor Xa
                        - Forms thrombin-antithrombin complex
                        - Neutralized by PF4 (platelet rich thrombi)
                    - Heparin Inducted Thrombocytopenia (HIT)
                        - Protamine sulfate (1mg to 100U) to reverse
                    - SE: Osteoporosis, increase bilirubin
                - B. Low-Molecular-Weight Heparin (LMWH) (Parenteral)
                    - Enoxaparin (Lovenox)
                        - Made from Unfractionated Heparin
                        - Greater capacity to potentiate factor Xa inhibition than thrombin due to being a short chain (2:1 – 4:1 Xa to iia)
                        - VTE + Cancer
                        - Dose independent, renal clearance, rare resistance, no monitoring
                        - Little aPTT affect, measure anti-Xa to monitor (Heparin-Xa)
                        - Every 4 hours
                        - Obesity, renal insufficiency, pregnant, valves
                - C. Antithrombin III Inhibitors (Indirect Factor Xa inhibitors) (Parenteral)
                    - Fondaparinux (Arixtra)
                        - (smallest heparin chains) AT3
                        - Can be used in surgical, ortho, VTE patients, only binds AT3, no thrombin rate inhibition, Xa only
                        - Renal cleared, can use in HIT, no antidote, no need to monitor
            - II. Direct Factor Xa Inhibitors
                - Factor Xa for monitoring
                    - Stroke prevent, long term anticoagulation in nonvalvular afib
                    - VTE treatment w/o cancer
                    - Reversal: 4F-PCC or Andexanet Alfa
                        - Modified factor Xa that competes with factor Xa Inhibitors for factor X
                - Apixaban (Eliquis)
                    - 10mg BID for 7 days
                    - 2.5-5mg PO BID
                - Rivaroxaban (Xarelto)
                    - 15mg BID for 21 days for VTE
                    - [20mg PO daily with dinner](https://www.pharmacytimes.com/view/clinical-overview-rivaroxaban-xarelto-for-multiple-cardiovascular-conditions){:target="_blank"}
                    - Renal Excretion
                - Edoxaban (Lixiana, Savaysa)
                    - 60mg PO daily
            - III. Direct Thrombin Inhibitors (DTIs) (Parenteral)
                - Inhibit Thrombin (IIa)
                - Univalent
                    - Argatroban
                        - Liver metabolism, not renal
                        - Used if HIT suspected
                        - aPTT, prolongs INR
                            - Measure Factor X instead to monitor warfarin
                    - Dabigatran (Pradaxa, Oral)
                        - 150mg PO BID or 75mg PO BID if Crcl = 15-30
                        - Direct Thrombin Inhibitor, Renally excreted, aPTT to monitor
                        - PPIs decrease absorption
                        - Reversal:
                            - <6 hours: Consider activated charcoal 
                            - Idarucizumab
                                - Humanized monoclonal antibody fragment
                                - Reverses within 1 hour
                            - Hemodialysis (68% can be removed in 4 hours)           
- Beta-Blockers
    - Metoprolol (Lopressor, Toprol XL)
        - Substrate of CYP2D6
            - 2-to-3-fold increase with Escitalopram, Citalopram, Duloxetine
            - 4-to-6-fold increase with Paroxetine, Fluoxetine, Bupropion
            - Sertraline, Venlafaxine, Mianserine, and Mirtazapine safer
            - Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly
                - [Link](https://pubmed.ncbi.nlm.nih.gov/29575226/){:target="_blank"}
                - [Link](https://pubmed.ncbi.nlm.nih.gov/21946596/){:target="_blank"}
        - CI: Sinus bradycardia, 1st degree AV block (PR >0.24), cardiogenic shock, SSS, WPW
- Calcium-Channel Blockers
    - Amlodipine
        - 30–50-hour half-life (longest)
            - No renal adjustment needed
        - [New CAD without HF to decrease hospitalizations for unstable angina and revascularization (PREVENT)](https://pubmed.ncbi.nlm.nih.gov/11004140/){:target="_blank"}
        - Non-FDA
            - Diabetic Nephropathy
                - [Combined therapy with ACEI/ARB exerts a greater antiproteinuric effect in T2DM](https://pubmed.ncbi.nlm.nih.gov/12484508/){:target="_blank"}
        - Side Effects
            - No use dependence or prolongation of QT
            - 10mg: Edema (10.8%), Headaches (7.3%), Palpitations/Fatigue (4.5%), Dizziness (3.4%), Nausea (2.9%), Flushing (2.6%), Abdominal Pain (1.6%)
                - [Link](https://pubmed.ncbi.nlm.nih.gov/31107359/){:target="_blank"}
            - Mixed hepatocellular-cholestatic pattern of DILI, usually complete recovery within 4-8 weeks when stopped
            - [Amlodipine + Erythromycin/Clarithromycin increase risk of hypotension and AKI 2/2 decreased CYP3A4 metabolism](https://pubmed.ncbi.nlm.nih.gov/24346990/){:target="_blank"}
            - [Increased risk of myopathy/Rhabdomyolysis with high-dose statins](https://pubmed.ncbi.nlm.nih.gov/28951665/){:target="_blank"}
- Diuretics
    - Thiazides
        - [General](https://pubmed.ncbi.nlm.nih.gov/16390355/){:target="_blank"}
        - MOA: Inhibit the reabsorption of Na+ and Cl- from the distal convoluted tubule, blocks Na-Cl symporter
        •	Intravascular volume depletion via diuresis reduces peripheral vascular resistance
        •	Indirectly increases the basolateral Na+/Ca2+ antiporter
        •	Better than ACEI in preventing strokes (reduced risk of CV events)
        - Use: Essential hypertension, edema, CHF, Nephrogenic DI, osteoporosis
        - SE: hyperGLUC (glucose, lipids, uric acid, calcium), Allergy, Gout
            - Dose-dependent hypokalemia
            - Metabolic Alkalosis, Azotemia
            - [Hyponatremia (typically within 1-2 weeks)](https://pubmed.ncbi.nlm.nih.gov/14631057/){:target="_blank"}
            - Euvolemic w/dizzy spells, lethargy, malaise, vomiting
                - May alternatively present as Orthostatic Hypotension/Volume depletion/increased risk of falls
                - Worse than loops
                - More common in older women with low BMI
                - 36% <130, age >70 had 3.9x higher risk
            - Give oral potassium supplements or potassium sparing diuretic (spironolactone)
            - Increased risk of T2DM, not first-line in T2DM
            - Falls
                - Discontinue in elderly with falls
                - [Increased Risk](https://pubmed.ncbi.nlm.nih.gov/29710140/){:target="_blank"}
                - Volume Depletion leading to orthostasis
    - SGLT-2s
        - [Effects on BP](https://pubmed.ncbi.nlm.nih.gov/31161798/){:target="_blank"}
        - [Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/25512787/){:target="_blank"}
        - [SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis](https://pubmed.ncbi.nlm.nih.gov/28003053/){:target="_blank"}
        - [Risk of Fourniers](https://www.ncbi.nlm.nih.gov/books/NBK532925/){:target="_blank"}
<br>
